UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Detection of biomarkers for lysosomal storage disorders using novel
technologies
van Breemen, M.J.
Publication date
2008
Link to publication
Citation for published version (APA):
van Breemen, M. J. (2008). Detection of biomarkers for lysosomal storage disorders using
novel technologies.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Table of contents
Prologue
Chapter 1 Introduction
Section I: Biomarkers for Gaucher disease
Chapter 2 Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases
Acta Paediatrica 94 (Suppl. 447) (2005) 43-46
Chapter 3 Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
Blood 103 (2004) 33-39
Chapter 4 Limitations in quantitation of the biomarker CCL18 in Gaucher disease blood samples by surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry Biochimica et Biophysica Acta 1764 (2006) 1626-1632
Chapter 5 Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1β levels in type I Gaucher disease
Biochimica et Biophysica Acta 1772 (2007) 788-796
Chapter 6 Correction in plasma macrophage inflammatory protein (MIP)-1β is dose dependent during the initial phase of enzyme replacement therapy of type I Gaucher disease
To be submitted as manuscript in shortened form
Chapter 7 Siblings with Gaucher disease type III: differential outcome due to timing of enzyme replacement and substrate reduction therapy Submitted
Chapter 8 Potential artefacts in proteome analysis of plasma of Gaucher patients due to protease abnormalities
To be submitted with minor modifications
Chapter 9 Assessing the statistical validity of proteomics based biomarkers Analytica Chimica Acta 592 (2007) 210-217
11
35
43
59
71
89
99
111
127
versie 17-04.qxp 17-4-2008 10:47 Pagina 7Chapter 10 Detection of mutant protein in complex biological samples: glucocerebrosidase mutations in Gaucher disease
Analytical Biochemistry 372 (2008) 52-61
Section II: Biomarkers for Fabry disease
Chapter 11 The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels
Journal of Inherited Metabolic Disease 30 (2007) 68-78
Chapter 12 Limited value of serum protein profiling for discrimination of patients suffering from Fabry disease
Submitted
Epilogue
Chapter 13 Biomarkers for lysosomal storage diseases: identification and application as exemplified by chitotriosidase in Gaucher disease Acta Paediatrica 97 (Suppl. 457) (2008) 7-14
Addendum 1 Proteomic profiling of plasma and serum of elderly patients with postoperative delirium
Submitted
Chapter 14 Summary and Discussion
Chapter 15 Samenvatting en Dankwoord
